ClinicalTrials.gg
TerminatedNCT04189445Updated Oct 8, 2025Results posted

Futibatinib in Patients With Specific FGFR Aberrations

A Phase 2 interventional study of Futibatinib in Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer and Myeloid or Lymphoid Neoplasms (MLN), sponsored by Taiho Oncology, Inc.. Terminated at 61 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor made a strategic decision to terminate the study considering enrollment challenges for some of the cohorts in the trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
471st of 1,864
115 · median 43
Started
2020
with 88 others
Phase 2
566 of 2,055
60 open now
Registered
1,387th of 2,055
by date

Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 471st largest by enrollment of the 1,864 interventional ones that give a count, is one of 89 that started in 2020, is one of 566 in phase 2, and was the 1,387th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,055 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.

Read the detailed description

Study TAS-120-202 is an open-label, multinational, 3-arm Phase 2 study evaluating the efficacy, safety, tolerability, PK, and pharmacodynamics of futibatinib in patients with FGFR aberrations. Eligible patients will be assigned to 1 of 3 treatment cohorts based on diagnosis and FGFR gene aberration status.

Patients will receive futibatinib at an oral dose of 20 mg once a day on a continuous 28-day cycle.

The study will enroll approximately:

  • Cohort A: 60 patients with locally advanced, advanced, or metastatic solid tumor harboring FGFR rearrangements other than primary brain tumor or iCCA;
  • Cohort B: 35 patients with locally-advanced, advanced, or metastatic gastric cancer or gastro-esophageal junction (GEJ) with FGFR2 amplification;
  • Cohort C: 20 patients with myeloid or lymphoid neoplasms (MLN) with FGFR1 rearrangements

Treatment in all cohorts will continue until disease progression, unacceptable toxicity, or any other of the criteria for treatment discontinuation is met. For patients who discontinue treatment for reasons other than disease progression, tumor assessments should be continued until radiologic disease progression is documented or until initiation of subsequent new anticancer therapy (whichever occurs first).

Patients will be followed for survival every 12 weeks (±2 weeks) until survival events (deaths) have been reported for 75% of enrolled patients or the study is terminated early by the Sponsor.

Additional cohorts may be added in the future in case of new emerging efficacy data.

03

Conditions studied

  • Advanced or Metastatic Solid Tumor
  • Advanced or Metastatic Gastric or Gastroesophageal Cancer
  • Myeloid or Lymphoid Neoplasms (MLN)

Keywords

  • Futibatinib
  • Gastric cancer
  • Gastro-esophageal junction cancer
  • Solid tumor
  • Myeloid neoplasm
  • Lymphoid neoplasm
  • FGFR
  • Amplification
  • Rearrangement
  • TAS-120
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status 0 or 1
  2. Known FGFR aberration status and tumor type that meet all of the criteria for 1 of the following cohorts:

    a. Cohort A

    i. -confirmed, locally-advanced, advanced, or solid tumors harboring a FGFR1-4

ii. per (RECIST) Version 1.1

iii. Had disease progression/recurrence after standard treatment for their cancer

b. Cohort B

i. Histologically-confirmed, locally-advanced, advanced, or metastatic gastric or gastroesophageal junction cancer harboring a FGFR2 amplification.

ii. Measurable disease per RECIST 1.1

iii. Received at least 2 prior systemic regimens for advanced/metastatic disease

iv. Experienced disease progression/recurrence during or after the most recent prior systemic treatment for advanced/metastatic gastric cancer or GEJ cancer

c. Cohort C

i. Confirmed myeloid or lymphoid neoplasms as defined by WHO criteria with a FGFR1 rearrangement

ii. Not a candidate for hematological stem cell transplant () or after HSCT and donor lymphocyte infusion, and progressed and not a candidate for other therapies

Exclusion criteria

Exclusion Criteria:

  1. History and/or current evidence of any of the following disorders:

    1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered in the opinion of the Investigator
    2. Ectopic mineralization/calcification including, but not limited to, soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator
    3. Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant in the opinion of the Investigator.
  2. Prior treatment with an FGFR inhibitor
  3. that are untreated or clinically or radiologically unstable (that is, have been stable for \<1 month)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Futibatinib (Cohort A)

    Participants with advanced or metastatic solid tumors harboring FGFR1-4 rearrangements received futibatinib 20 mg, oral tablets, once a day on a continuous 28-day cycle up to a maximum of 841 days.

    Drug: Futibatinib

  • Experimental
    Futibatinib (Cohort B)

    Participants with advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification received futibatinib 20 mg, oral tablets, once a day on a continuous 28-day cycle up to a maximum of 297 days.

    Drug: Futibatinib

  • Experimental
    Futibatinib (Cohort C)

    Participants with myeloid or lymphoid neoplasm harboring FGFR1 rearrangement were to receive futibatinib 20 mg, oral tablets, once a day on a continuous 28-day cycle until disease progression, unacceptable toxicity or other treatment discontinuation criteria are met.

    Drug: Futibatinib

Interventions

  • Futibatinib tablets were dosed orally every day on a continuous 28-day cycle

    Also known as: TAS-120

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B

    ORR was defined as the percentage of participants experiencing a best overall response of partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors, RECIST version 1.1), based on IRC of radiological images. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  2. Complete Response (CR) Rate in Cohort C

    CR rate was defined as the percentage of participants who achieved a CR (per response criteria for myeloid or lymphoid neoplasm) based on investigator assessment of imaging, peripheral blood, and bone marrow. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

Secondary outcomes

  1. ORR Based on Investigator Assessment in Cohorts A and B

    ORR was defined as the percentage of participants experiencing a best overall response of PR or CR (per RECIST 1.1), based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  2. Duration of Response (DOR) Based on IRC in Cohorts A, B and C

    DOR was defined as the time from the first documentation of response (CR or PR in based on IRC) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  3. DOR Based on Investigator Assessment in Cohorts A, B and C

    DOR was defined as the time from the first documentation of response (CR or PR in based on Investigator Assessment) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  4. Progression- Free Survival (PFS) Based on IRC in Cohorts A, B and C

    PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on IRC), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  5. PFS Based on Investigator Review in Cohorts A, B and C

    PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on Investigator Review), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  6. Overall Survival (OS) in Cohorts A, B and C

    OS was defined as the time from the date of first dose to the death date. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.

    Time frame: Up to 31 months

  7. Disease Control Rate (DCR) Based on IRC in Cohort A and B

    DCR was defined as the percentage of participants experiencing a best overall response of stable disease (SD), PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  8. DCR Based on Investigator Review in Cohort A and B

    DCR was defined as the percentage of participants experiencing a best overall response of SD, PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)

  9. CR+ Complete Response With Incomplete Hematological Recovery (CRi) Rate in Cohort C

    CR+CRi rate was defined as the percentage of participants who achieved a CR or CRi.

    Time frame: Up to 31 months

  10. Duration of CR in Cohort C

    Duration of CR was defined as the time from the first documentation of CR to the first documentation of recurrence or death due to any cause, whichever occurs first.

    Time frame: Up to 31 months

  11. Duration of CR+CRi in Cohort C

    Duration of CR+CRi was defined as the time from the first documentation of CR or CRi to the first documentation of disease relapse or death due to any cause, whichever occurs first.

    Time frame: Up to 31 months

  12. Complete Cytogenetic Response (CCyR) Rate in Cohort C

    CCyR rate was defined as the percentage of participants who achieved a CCyR.

    Time frame: Up to 31 months

  13. Partial Cytogenetic Response (PCyR) Rate in Cohort C

    PCyR rate was defined as the percentage of participants who achieved a PCyR.

    Time frame: Up to 31 months

  14. Relapse-free Survival (RFS) in Cohort C

    RFS was defined as the time from first documentation of CR to the date of death (any cause) or disease relapse or death due to any cause, whichever occurs first.

    Time frame: Up to 31 months

  15. Event-free Survival (EFS) in Cohort C

    EFS was defined as the time from first dose of study therapy to treatment failure, disease relapse after CR, or participant death due to any cause, whichever occurs first.

    Time frame: Up to 31 months

  16. Number of Participants With Treatment Emergent Adverse Events (TEAEs) - Cohort A, B and C

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug. A treatment-emergent AE (TEAE) is defined as an AE that is starting or worsening at the time of or after the first dose of study drug administration and within 30 days after the last dose of study drug, and does not necessarily have a causal relationship to the use of the study drug.

    Time frame: From the first dose of study drug up to 30 days after the last dose (Up to 31 months)

07

Results

Posted Oct 8, 2025
Limitations and caveats
The Sponsor made a strategic decision to terminate the study considering enrollment challenges for some of the cohorts in the trial.

Participant flow

Participants took part in the study from 05 August 2020 to 11 November 2024.

Participant flow — Overall Study
MilestoneFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
Started87280
Completed000
Not completed87280
Withdrew: Withdrawal of consent810
Withdrew: Study terminated by sponsor2530
Withdrew: Death54240

Outcome measures

PrimaryObjective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B

ORR was defined as the percentage of participants experiencing a best overall response of partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors, RECIST version 1.1), based on IRC of radiological images. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B
percentage of participantsFutibatinib (Cohort A)Futibatinib (Cohort B)
Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B6.9 (2.6 to 14.4)17.9 (6.1 to 36.9)
PrimaryComplete Response (CR) Rate in Cohort C

CR rate was defined as the percentage of participants who achieved a CR (per response criteria for myeloid or lymphoid neoplasm) based on investigator assessment of imaging, peripheral blood, and bone marrow. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)

No measurements were reported for this outcome.

SecondaryORR Based on Investigator Assessment in Cohorts A and B

ORR was defined as the percentage of participants experiencing a best overall response of PR or CR (per RECIST 1.1), based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Number · percentage of participants
ORR Based on Investigator Assessment in Cohorts A and B
percentage of participantsFutibatinib (Cohort A)Futibatinib (Cohort B)
ORR Based on Investigator Assessment in Cohorts A and B9.2 (4.1 to 17.3)10.7 (2.3 to 28.2)
SecondaryDuration of Response (DOR) Based on IRC in Cohorts A, B and C

DOR was defined as the time from the first documentation of response (CR or PR in based on IRC) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Median · months
Duration of Response (DOR) Based on IRC in Cohorts A, B and C
monthsFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
Duration of Response (DOR) Based on IRC in Cohorts A, B and C5.6 (3.5 to NA)3.9 (2.1 to NA)—
SecondaryDOR Based on Investigator Assessment in Cohorts A, B and C

DOR was defined as the time from the first documentation of response (CR or PR in based on Investigator Assessment) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Median · months
DOR Based on Investigator Assessment in Cohorts A, B and C
monthsFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
DOR Based on Investigator Assessment in Cohorts A, B and C5.6 (3.0 to NA)5.6 (2.0 to NA)—
SecondaryProgression- Free Survival (PFS) Based on IRC in Cohorts A, B and C

PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on IRC), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Median · months
Progression- Free Survival (PFS) Based on IRC in Cohorts A, B and C
monthsFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
Progression- Free Survival (PFS) Based on IRC in Cohorts A, B and C1.9 (1.8 to 3.5)2.9 (1.8 to 3.7)—
SecondaryPFS Based on Investigator Review in Cohorts A, B and C

PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on Investigator Review), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Median · months
PFS Based on Investigator Review in Cohorts A, B and C
monthsFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
PFS Based on Investigator Review in Cohorts A, B and C3.3 (1.9 to 3.8)3.3 (2.1 to 3.7)—
SecondaryOverall Survival (OS) in Cohorts A, B and C

OS was defined as the time from the date of first dose to the death date. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.

Time frame:
Up to 31 months
Reported as:
Median · months
Overall Survival (OS) in Cohorts A, B and C
monthsFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
Overall Survival (OS) in Cohorts A, B and C11.1 (7.3 to 15.6)5.9 (3.9 to 8.9)—
SecondaryDisease Control Rate (DCR) Based on IRC in Cohort A and B

DCR was defined as the percentage of participants experiencing a best overall response of stable disease (SD), PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Based on IRC in Cohort A and B
percentage of participantsFutibatinib (Cohort A)Futibatinib (Cohort B)
Disease Control Rate (DCR) Based on IRC in Cohort A and B37.9 (27.7 to 49.0)50.0 (30.6 to 69.4)
SecondaryDCR Based on Investigator Review in Cohort A and B

DCR was defined as the percentage of participants experiencing a best overall response of SD, PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (Up to 31 months)
Reported as:
Number · percentage of participants
DCR Based on Investigator Review in Cohort A and B
percentage of participantsFutibatinib (Cohort A)Futibatinib (Cohort B)
DCR Based on Investigator Review in Cohort A and B52.9 (41.9 to 63.7)64.3 (44.1 to 81.4)
SecondaryCR+ Complete Response With Incomplete Hematological Recovery (CRi) Rate in Cohort C

CR+CRi rate was defined as the percentage of participants who achieved a CR or CRi.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryDuration of CR in Cohort C

Duration of CR was defined as the time from the first documentation of CR to the first documentation of recurrence or death due to any cause, whichever occurs first.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryDuration of CR+CRi in Cohort C

Duration of CR+CRi was defined as the time from the first documentation of CR or CRi to the first documentation of disease relapse or death due to any cause, whichever occurs first.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryComplete Cytogenetic Response (CCyR) Rate in Cohort C

CCyR rate was defined as the percentage of participants who achieved a CCyR.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryPartial Cytogenetic Response (PCyR) Rate in Cohort C

PCyR rate was defined as the percentage of participants who achieved a PCyR.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryRelapse-free Survival (RFS) in Cohort C

RFS was defined as the time from first documentation of CR to the date of death (any cause) or disease relapse or death due to any cause, whichever occurs first.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryEvent-free Survival (EFS) in Cohort C

EFS was defined as the time from first dose of study therapy to treatment failure, disease relapse after CR, or participant death due to any cause, whichever occurs first.

Time frame:
Up to 31 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) - Cohort A, B and C

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug. A treatment-emergent AE (TEAE) is defined as an AE that is starting or worsening at the time of or after the first dose of study drug administration and within 30 days after the last dose of study drug, and does not necessarily have a causal relationship to the use of the study drug.

Time frame:
From the first dose of study drug up to 30 days after the last dose (Up to 31 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) - Cohort A, B and C
ParticipantsFutibatinib (Cohort A)Futibatinib (Cohort B)Futibatinib (Cohort C)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) - Cohort A, B and C8727—

Adverse events

Collected over From the first dose of study drug up to 30 days after the last dose (Up to 31 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Futibatinib (Cohort A)54/87 (62.1%)23/87 (26.4%)86/87 (98.9%)
Futibatinib (Cohort B)24/28 (85.7%)6/28 (21.4%)27/28 (96.4%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventFutibatinib (Cohort A)Futibatinib (Cohort B)
VomitingGastrointestinal disorders0/872/28
DyspnoeaRespiratory, thoracic and mediastinal disorders5/870/28
General physical health deteriorationGeneral disorders2/871/28
PneumoniaInfections and infestations2/871/28
Decreased appetiteMetabolism and nutrition disorders2/871/28
Abdominal painGastrointestinal disorders0/871/28
Upper gastrointestinal haemorrhageGastrointestinal disorders0/871/28
HaemobiliaHepatobiliary disorders0/871/28
Spinal compression fractureInjury, poisoning and procedural complications0/871/28
Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/871/28
Most frequent other events
Showing 10 of 213
Most frequent other events
EventFutibatinib (Cohort A)Futibatinib (Cohort B)
HyperphosphataemiaMetabolism and nutrition disorders70/8725/28
DiarrhoeaGastrointestinal disorders36/876/28
Decreased appetiteMetabolism and nutrition disorders18/8710/28
ConstipationGastrointestinal disorders28/873/28
Aspartate aminotransferase increasedInvestigations15/877/28
Dry mouthGastrointestinal disorders20/871/28
Alanine aminotransferase increasedInvestigations19/876/28
NauseaGastrointestinal disorders8/876/28
AnaemiaBlood and lymphatic system disorders16/873/28
FatigueGeneral disorders15/874/28

Baseline characteristics

All treated population included all participants who received at least 1 dose of study drug. No participant was enrolled in Cohort C, hence no data was collected.

Age, Continuous
Age, Continuous(years)Futibatinib (Cohort A)Futibatinib (Cohort B)Total
Mean60.0 ± 12.4755.6 ± 13.7758.9 ± 12.87
Sex: Female, Male
Sex: Female, Male(Participants)Futibatinib (Cohort A)Futibatinib (Cohort B)Total
Female471663
Male401252
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Futibatinib (Cohort A)Futibatinib (Cohort B)Total
Race — Caucasian/White29332
Race — Black or African American101
Race — Asian362460
Race — Other101
Race — Unknown20121
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Futibatinib (Cohort A)Futibatinib (Cohort B)Total
Ethnicity — Hispanic or Latino314
Ethnicity — Not Hispanic or Latino622688
Ethnicity — Unknown22123
08

Study locations

61 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234-2165, United States
  • UCLA Medical Center
    Los Angeles, California 90404, United States
  • Georgetown University - Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20007, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215-5400, United States
  • Henry Ford Hospital
    Woodhaven, Michigan 48183, United States
  • Mercy Clinic Oncology and Hematology - Coletta
    Oklahoma City, Oklahoma 73120, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 53705, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • The University of Texas M. D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Centre Antoine Lacassagne
    Nice, Alpes Maritimes 06200, France
  • Centre Paul Strauss
    Strasbourg, Bas Rhin 67000, France
  • Centre Georges François Leclerc
    Dijon, Côte-d'Or 21079, France
  • Institut Bergonié
    Bordeaux, Gironde 33076, France
  • Hôpital Saint-Louis
    Paris, Paris 75475, France
  • Centre Léon Bérard
    Lyon, Rhone 69008, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhone 69495, France
  • Institut Gustave Roussy
    Villejuif, Val De Marne 94805, France
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitaetsklinikum Koeln
    Cologne, North Rhine-Westphalia 50924, Germany
  • The University of Hong Kong
    Hong Kong, Hong Kong
  • Hong Kong United Oncology Centre
    Jordon, 0000, Hong Kong
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
    Meldola, Forli - Cesena 47014, Italy
  • Ospedale Sacro Cuore Don Calabria
    Negrar, Verona 37024, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Florence, 50134, Italy
  • IEO Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Trento)
    Verona, 37124, Italy
  • Aichi Cancer Center Hospital
    Nagoya, Aichi-ken 464-8681, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba 277-8577, Japan
  • NHO Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Osaka University Hospital
    Suita-shi, Osaka 565-0871, Japan
  • National Cancer Center Hospital
    Chūōku, Tokyo-To 104-0045, Japan
  • Antoni van Leeuwenhoek
    Amsterdam, 1066 CX, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 AA, Netherlands
  • Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos
    Lisbon, 1169-050, Portugal
  • Fundação Champalimaud
    Lisbon, 4099-001, Portugal
  • Centro Hospitalar do Porto, E.P.E - Hospital de Santo Antonio
    Porto, 4099-001, Portugal
  • National University Cancer Institute
    Singapore, 119074, Singapore
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario HM Madrid Sanchinarro
    Madrid, 28050, Spain
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Instituto Valenciano de Oncologia IVO
    Valencia, 46009, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Karolinska universitetssjukhuset - Solna
    Solna, 171 64, Sweden
  • Akademiska Sjukhuset
    Uppsala, 75185, Sweden
  • Acibadem Adana Hospital
    Adana, 01130, Turkey (Türkiye)
  • Acibadem Maslak Hospital
    Istanbul, 34457, Turkey (Türkiye)
  • Namik Kemal University
    Tekirdağ, 59100, Turkey (Türkiye)
  • Sarah Cannon Research Institute UK
    London, Greater London W1G 6AD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Nov 2024, 51 months.

Results were first posted in Oct 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 6, 2019
StartActual
Aug 5, 2020
Primary completionActual
Nov 11, 2024
CompletionActual
Nov 11, 2024
Results first posted
Oct 8, 2025
Last update
Oct 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04189445
Responsible party
Sponsor
First posted
Dec 6, 2019
Start date
Aug 5, 2020
Primary completion
Nov 11, 2024
Completion
Nov 11, 2024
Results posted
Oct 8, 2025
Last update
Oct 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Futibatinib

Start the discussion